September 28, 2017
Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”